Phase 4 Uveitis Trial, Completed

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are willing to follow all study rules and are available for the full length of the study
• You are 2 years of age or older
• You were diagnosed with juvenile idiopathic arthritis (a type of childhood arthritis) or chronic eye inflammation before age 16 (you can be older than 16 when joining the trial)
• You have a confirmed diagnosis of eye inflammation linked to juvenile idiopathic arthritis or chronic eye inflammation with no other known cause
• Your eye inflammation has been well controlled for at least 12 months in a row, based on specific eye exam measurements
• If your eye inflammation is linked to juvenile idiopathic arthritis, your joint disease has also been well controlled for at least 12 months, as confirmed by a specialist children's doctor
• You have been taking adalimumab (or a very similar approved medicine) for at least 12 months in a row
• You have been on a stable, every-two-weeks dose of adalimumab (or similar medicine) for at least 180 days
• If you are taking the similar version of adalimumab (a biosimilar), you have been on it for at least 90 days
• If you are also taking certain other medicines to control your immune system (such as methotrexate or similar drugs), your dose is within specific limits and has been stable for at least 90 days (confirm with trial site)
• If you are using steroid eye drops, you are using no more than 2 drops per day of a standard strength and the dose has been stable for at least 90 days
• You are willing to limit alcohol during the study
• You agree not to receive any live vaccines during the study
• If you are able to have children, you agree to use highly effective birth control for at least 28 days before the study starts and throughout the study
• The trial doctor considers it appropriate for you to continue on adalimumab or a dummy medicine (placebo)
• You have no medical reasons that would prevent you from taking adalimumab

Who may not be able to join:

• You have had eye surgery in the last 90 days or have eye surgery planned in the next 12 months
• You have a severe clouding of the lens or other blockage in both eyes that prevents a clear view of the back of the eye
• You have had persistently very low eye pressure (below a safe level) in either eye for 90 days or more
• You have taken steroid tablets by mouth or had a steroid injection into the eye in the last 12 months
• You have used anti-inflammatory eye drops (NSAID type) in the last 90 days
• You currently have a sudden, active flare of eye inflammation with symptoms such as redness, floaters, pain, or sensitivity to light
• You are pregnant or breastfeeding (pregnancy tests will be done at the start and throughout the study for anyone who could become pregnant)
• There is fluid build-up in certain layers at the back of either eye
• You have previously had serious safety or tolerability problems with adalimumab
• You have a history of cancer, active tuberculosis (a type of serious infection), or hepatitis B (a liver infection)
• You have another medical condition that is expected to affect which treatments you can receive during the study
• Your most recent blood test results (taken within the last 90 days) show certain abnormal levels in your blood counts or liver/kidney function (confirm with trial site)

There are no restrictions based on sex, race, or ethnicity for this study.

Important: Always verify eligibility with the trial site directly before applying.